C1GALT1 expression predicts poor survival in osteosarcoma and is crucial for ABCC1 transporter‐mediated doxorubicin resistance
The Journal of Pathology · 2025
DOI: 10.1002/path.6384 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Pathology, 2025. Verfasst von Chun-Wei Liu und 11 weiteren Autor:innen. Beteiligte Einrichtung: Graduate Institute of Anatomy and Cell Biology, National Taiwan University College of Medicine, Taipei, Taiwan. Hauptthemen laut MEDLINE: Osteosarcoma, Doxorubicin, Galactosyltransferases, Drug Resistance, Neoplasm. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Taiwan University Hospital, Ministry of Science and Technology.
Abstract (Originalsprache)
Osteosarcoma is an aggressive bone malignancy with a high propensity for drug resistance and metastasis, leading to poor clinical outcomes. This study investigates the role of core 1 β1,3‐galactosyltransferase 1 (C1GALT1) in osteosarcoma, focusing on its implications in chemoresistance. Our findings reveal that high expression of C1GALT1 is associated with advanced stages, adverse overall survival, and increased recurrence rates. Elevated levels of C1GALT1 were observed in doxorubicin‐selected osteosarcoma cells, where its suppression significantly promoted doxorubicin‐induced apoptosis and reduced drug efflux. Pharmacological inhibition of C1GALT1 using itraconazole replicated these effects, suggesting a potential therapeutic strategy to overcome chemoresistance. Additionally, we identified the involvement of the ATP‐binding cassette (ABC) transporter ABCC1 in the drug‐resistance phenotype mediated by C1GALT1. C1GALT1‐mediated O‐glycan changes were found to influence the cell‐surface targeting and lysosomal degradation of ABCC1, thereby modulating its efflux capacity. In vitro and in vivo studies confirmed that C1GALT1 impacts ABCC1 expression and function, further supporting its role in osteosarcoma chemoresistance. These results highlight the clinical relevance of C1GALT1 as a biomarker for prognosis and a potential therapeutic target for osteosarcoma. © 2025 The Author(s). The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Graduate Institute of Anatomy and Cell Biology, National Taiwan University College of Medicine, Taipei, Taiwan.
- Department of Biochemistry and Molecular Medicine, National Dong Hwa University, Hualien, Taiwan.
- Department of Pediatrics, National Taiwan University Hospital, National Taiwan University College of Medicine, Taipei, Taiwan.
- Department of Anatomy, School of Medicine, Chang Gung University, Taoyuan, Taiwan.
- Neuroscience Research Center, Chang Gung Memorial Hospital, Linkou Medical Center, Taoyuan, Taiwan.
- Graduate Institute of Biomedical Sciences, College of Medicine, Chang Gung University, Taoyuan, Taiwan.
ORCID-Profile: Neng-Yu Lin
Förderung
- National Taiwan University Hospital
- Ministry of Science and Technology
Zitieren
APA
Liu, C. W., Huang, J. H., Chang, H. H., Chen, C. H., Tsai, Y. H., Chen, W. L., Lin, J. A., Chang, H. L., Chen, C. C., Lin, M. C., Huang, M. C., & Lin, N. Y. (2025). C1GALT1 expression predicts poor survival in osteosarcoma and is crucial for ABCC1 transporter‐mediated doxorubicin resistance. The Journal of Pathology. https://doi.org/10.1002/path.6384
Vancouver
Liu CW, Huang JH, Chang HH, Chen CH, Tsai YH, Chen WL, et al. C1GALT1 expression predicts poor survival in osteosarcoma and is crucial for ABCC1 transporter‐mediated doxorubicin resistance. The Journal of Pathology. 2025. doi:10.1002/path.6384
BibTeX
@article{Liu2025,
author = {Liu, Chun-Wei and Huang, Jing-Hui and Chang, Hsiu-Hao and Chen, Chia-Hua and Tsai, Yi-Huan and Chen, Wei-Li and Lin, Jung-An and Chang, Hsiu-Ling and Chen, Cheng-Chang and Lin, Mei-Chun and Huang, Min-Chuan and Lin, Neng-Yu},
title = {C1GALT1 expression predicts poor survival in osteosarcoma and is crucial for ABCC1 transporter‐mediated doxorubicin resistance},
journal = {The Journal of Pathology},
year = {2025},
doi = {10.1002/path.6384}
}
EUVIMED